Implications of somatostatin analogues in the treatment of acromegaly

Gariani, Karim; Meyer, Patrick; Philippe, Jacques

doi:10.17925/EE.2013.09.02.132

Scientific article

Review

English

Implications of somatostatin analogues in the treatment of acromegaly

ContributorsGariani, Karim; Meyer, Patrick; Philippe, Jacques

Published inEuropean endocrinology, vol. 9, no. 2, p. 132-135

Publication date2013

Abstract

Octreotide has an important role in the medical management of acromegaly. Its place in the management of acromegaly as an adjuvant therapy after neurosurgery is well established with a well-demonstrated efficacy. It can also be used in certain clinical conditions as a neoadjuvant treatment. Clinicians and patients should be aware of the possible side effects of octreotide treatment.

Keywords

Acromegaly
Octreotide
Side effects
Somatostatin analogues
Treatment

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

MASLD/MASH et résistance à l'insuline (997)

Citation (ISO format)

GARIANI, Karim, MEYER, Patrick, PHILIPPE, Jacques. Implications of somatostatin analogues in the treatment of acromegaly. In: European endocrinology, 2013, vol. 9, n° 2, p. 132–135. doi: 10.17925/EE.2013.09.02.132

Article (Published version)

Identifiers

PID : unige:142949
DOI : 10.17925/EE.2013.09.02.132
PMID : 29922369

Additional URL for this publicationhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003582/

Journal ISSN1758-3772

350views

183downloads

Creation11/08/2020 10:56:00

First validation11/08/2020 10:56:00

Update time06/01/2025 08:25:46

Status update06/01/2025 08:25:46

Last indexation06/01/2025 08:28:27

Archive ouverte UNIGE

Implications of somatostatin analogues in the treatment of acromegaly

Technical informations